{"id":104672,"name":"EXELIXIS, INC.","slug":"exelixis-inc","state":"CA","description":"Oncology-focused biotechnology company","totalSpending":1490000,"filings":23,"yearlySpending":[{"year":2018,"income":20000},{"year":2019,"income":250000},{"year":2020,"income":200000},{"year":2021,"income":180000},{"year":2022,"income":180000},{"year":2023,"income":300000},{"year":2024,"income":180000},{"year":2025,"income":180000}],"firms":["ARNOLD & PORTER KAYE SCHOLER LLP"],"lobbyists":["DANA WEEKES","KRISTINE BLACKWOOD","PARI MODY","EUGENIA PIERSON","CJ MAHLER","MICKAYLA STOGSDILL","CASEY BROUHARD","DAVID SKILLMAN","BOBBY MCMILLIN","PETER DUYSHART","SONJA NESBIT","TWINKLE PATEL"],"issues":["HCR","MMM","TAX",null,"CPT"],"sampleDescriptions":["Issues related to access, coverage, and payment for cancer drugs.","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. CREATES Act of 2019 (S. 340/H.R. 965). Lower Health Care Costs Act (S. 1895).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Prescription Drug Pricing Reduction Act (S. 2543). Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Lower Health Care Costs Act (S. 1895).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program.","Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); H.R.5376, the Build Back Better Act.","Issues related to R&D tax credits.","Issues related to access, coverage, and payment for cancer drugs. Issues regarding Medicare Part D benefit redesign. Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3); Lower Costs, More Cures Act of 2021 (S. 2164/H.R. 19); Build Back Better Act (H.R. 5376); and the Inflation Reduction Act (H.R. 5376).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation.","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act).","Issues related to R&D tax credits, including the Tax Relief for American Families and Workers Act of 2024 (H.R. 7024).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program, including the Bipartisan 340B Senate Working Group's discussion draft of the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act). Issues related to biopharmaceutical intellectual property and patent matters.","Issues related to biopharmaceutical intellectual property and patent matters.","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 5029, 118th Congress).","Issues related to research and development (R&D) tax credits.","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the Inflation Reduction Act (Pub. L. No. 117-169), including implementation. Issues related to the Small Biotech Innovation Act (S. 1930 / H.R. 3731).","Issues related to access, coverage, and payment for cancer drugs. Issues regarding the 340B program. Issues related to biopharmaceutical intellectual property and patent matters."],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}